Biosite POC (point-of-care) D-Dimer test:
This article was originally published in Clinica
Biosite has received US FDA 510(k) clearance to sell its point-of-care (POC) Triage D-Dimer test for helping doctors assess patients suspected of having thromboembolic events, including pulmonary embolism (PE). Portable and easy-to-use, the test can be used in the emergency room (ER) or at the patient's bedside, said the San Diego, California firm. The company added that a recent study showed that a POC clinical protocol for assessing PE, using an available latex-agglutination test for D-Dimer, doubled the number of patients evaluated for the condition and decreased length of stay in the ER, without increasing the need for vascular imaging. At least 650,000 cases of PE occur annually in the US.